

ONLINE APPENDIX

Table A1. *Participating countries and used enzyme immunoassays indicating antibodies against measles, mumps, rubella with the concerning detection range*

Country	Measles			Mumps			Rubella		
	Kit producer	Units	Test limits‡	Kit producer	Units	Test limits‡	Kit producer	Units	Test limits‡
Germany (RL)	DB	IU	> 0.01	DB	titre	> 10	DB	IU	> 1
Australia*	DB	IU	> 0.01	DB*	titre	> 10	DB*	IU	> 1
Belgium	HC	AU	> 0.03	HC	titre	> 0.5	DO	IU	> 1
Bulgaria	HC	AU	> 0.03	HC	titre	> 0.03	PL	IU	10 -500
Cyprus	ER	IU	0.05-5	ER	AU	2 - 200	Radim	IU	1-200
Czech Republic	SK	AU	20-3200	SK	AU	> 20	DO	IU	> 1
Eire	Biotech	ISR	> 0.1	Captia	ISR	> 0.1	Biokit	IU	> 5
England & Wales	DB	IU	> 0.01	DB	titre	> 10	Microgen	IU	1-80
Finland*	DB*	IU	> 0.006	DB	titre	> 20	DB*	IU	> 1
Greece*	DB	IU	> 0.01	DB	titre	10 - 8000	DB	IU	> 1
Hungary	VR	IU	0.05-5	VR	AU	3 - 2000	DO	IU	1-200
Israel†	DB	IU	> 0.017	DB	titre	> 22	DB	IU	> 2
Latvia	HU	IU	0.05-5.5	HU	AU	2 - 230	PL	IU	10-500
Lithuania	DB	IU	> 0.006	DB	titre	> 10	DB	IU	> 1
Luxembourg	DB	IU	> 0.01	DB	titre	> 10	DB	IU	> 1
Malta	VR	IU	0.05-5	VR	AU	150	Abbott	IU	1-500
The Netherlands*	In-house	IU	> 0.02	In-house	AU	> 4	In-house	IU	> 3
Romania	DB	IU	> 0.01	DB	titre	> 10	DB	IU	> 1
Slovakia	VT	AU	> 9	VT	AU	> 9	DO	IU	> 10
Slovenia	DB	IU	> 0.01	DB	titre	> 7	DB	IU	> 1
Spain†	DB	IU	> 0.01	DB	titre	> 10	DB*	IU	> 1
Sweden†	In-house	IU	> 0.12	DB	titre	> 10	In-house	IU	> 10

DB, Dade Behring; ER, Euroimmun; HC, Hycor; HU, Human; SK, Seiken; VR, VirionSerion; VT, Virotech; DO, Dia-Sorin; PL, Platelia; AU, arbitrary units; IU, international units; ISR, index; RL, reference laboratory.

* Countries took part for quality assurance only.

† Countries performed back-standardization.

‡ Test limits of some participants indicate values below the cut-off values provided by the kit producer.

Table A2. Distribution of antibody values against measles, mumps and rubella virus in the 151 sera of the reference panel, detected by EIA (Dade Behring); mean values of four tests in the reference laboratory

	Measles antibodies (IU/ml)		Mumps antibodies (titres)		Rubella antibodies (IU/ml)	
	Cut-offs	n	Cut-offs	n	Cut-offs	n
Negative	< 0.15	28	< 1:230	40	< 4	35
Equivocal	0.15–0.35	4	1:230–1:500	11	4–7	4
Positive						
Low	0.351–0.99	22	1:501–1:1200	33	7.1–35	22
Medium	1.0–3.0	40	1:1201–1:4000	50	35.1–100	31
High	> 3.0	57	> 1:4000	17	> 100	59




Fig. A1. Comparison of antibody values of the MMR reference panel measured by EIA in the respective country (y axis) plotted against the EIA results of the reference laboratory (Germany, x axis) on the \log_{10} scale. Open squares denote outliers, dotted lines denote the equivocal ranges, solid lines are the regression models. Measles antibodies (*top row*), mumps antibodies (*middle row*), rubella antibodies (*bottom row*). \dagger Participants performed back-standardization.




Fig. A2. Percentage of sera with positive (including equivocal) measles antibody values before (---●---) and after (—■—) the standardization procedure for seroprevalence data of Cyprus; sera collected in 2003.